Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

31.95 -0.10 (-0.31%)
Streaming Delayed Price Updated: 10:06 AM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a... 
Via Benzinga
News headline image
Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage ↗
 
Via Benzinga
News headline image
Hold Pfizer Today With Catalysts for Further Growth Tomorrow
Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives. 
Via MarketBeat
News headline image
The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol ↗
This could offer an improvement over CRISPR, which requires cutting DNA. 
Via Investor's Business Daily
News headline image
BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap... 
Via Benzinga
News headline image
Expert Ratings For Beam Therapeutics ↗
Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the f... 
Via Benzinga
News headline image
The 3 Leaders of the Gene Editing Revolution ↗
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
News headline image
7 Moonshot Investments Upending a $10 Trillion Industry ↗
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
News headline image
Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics ↗
Verve Therapeutics Inc (NASDAQ: VERV) entered into an amended and restated collaboration and license Agreement with Beam Therapeutics Inc (NASDAQ: 
Via Benzinga
News headline image
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit? ↗
The FDA's advisors recently backed Pfizer's Covid shot for young children. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
News headline image
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗
A rebound from Monday's lows faded, with the key indexes all down for the week. 
Via Investor's Business Daily
News headline image
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
News headline image
Pfizer Continues Its Covid Makeover: What's Next For This Hot Stock? ↗
How the pandemic continued a transformation Pfizer says began years ago. 
Via Investor's Business Daily
News headline image
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
News headline image
Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs ↗
Pfizer Inc (NYSE: PFE) and Beam Therapeutics Inc (NASDAQ: BEAM) have announced an exclusive four-year research collaboration focused on in vivo ... 
Via Benzinga
News headline image
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics ↗
The companies hope to cure diseases of the liver, muscle and central nervous system. 
Via Investor's Business Daily
News headline image
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
From Pfizer Inc.
Via Business Wire
News headline image
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick ↗
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022 ↗
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE: 
Via Benzinga
News headline image
Got $1,000? Check Out These 3 Top Biotech Stocks ↗
Two big biotechs and one smaller one that could be winners over the long term. 
Via The Motley Fool
News headline image
Being First Is Not Enough For Crispr Therapeutics ↗
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. 
Via InvestorPlace
News headline image
In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing ↗
Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner... 
Via Benzinga
News headline image
Cathie Wood's Buying Beam Therapeutics -- Should You? ↗
Can this high-flying gene-editing stock keep on climbing for new investors? 
Via The Motley Fool
News headline image
Looking Into Beam Therapeutics's Return On Capital Employed ↗
Beam Therapeutics (NASDAQ:BEAM) brought in sales totaling $763.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 18.08%, resulting in a... 
Via Benzinga
News headline image
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology ↗
Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ: 
Via Benzinga
News headline image
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week ↗
A key gene-editing readout had Cathie Wood shuffling her portfolio. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.